

# Josã© L Piã±ana

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1692914/publications.pdf>

Version: 2024-02-01

130  
papers

2,630  
citations

201674

27  
h-index

254184

43  
g-index

130  
all docs

130  
docs citations

130  
times ranked

3514  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>SARSâ€CoV</scp>â€2â€reactive antibody detection after <scp>SARSâ€CoV</scp>â€2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. American Journal of Hematology, 2022, 97, 30-42.	4.1	52
2	HEV infection in stem cell transplant recipientsâ€™ retrospective study of EBMT Infectious Diseases Working Party. Bone Marrow Transplantation, 2022, 57, 167-175.	2.4	6
3	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma, 2022, 63, 538-550.	1.3	8
4	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances, 2022, 6, 848-853.	5.2	5
5	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	17.0	26
6	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. Cancers, 2022, 14, 2673.	3.7	4
7	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	2.4	10
8	Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Annals of Hematology, 2022, 101, 2053-2067.	1.8	7
9	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 5167-5172.	5.0	8
10	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	4.7	11
11	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection, 2021, 49, 215-231.	4.7	63
12	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	2.2	2
13	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation, 2021, 56, 1281-1290.	2.4	3
14	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. Bone Marrow Transplantation, 2021, 56, 992-996.	2.4	3
15	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2021, 223, 1564-1575.	4.0	21
16	Central Nervous System Involvement in Epsteinâ€Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 261.e1-261.e7.	1.2	4
17	Adoptive transfer of ex vivo expanded SARSâ€CoVâ€2â€specific cytotoxic lymphocytes: A viable strategy for COVIDâ€19 immunosuppressed patients?. Transplant Infectious Disease, 2021, 23, e13602.	1.7	9
18	An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 4773-4779.	5.0	1

#	ARTICLE	IF	CITATIONS
19	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. <i>Bone Marrow Transplantation</i> , 2021, 56, 1919-1928.	2.4	13
20	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
21	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	1.7	5
22	Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic. <i>Bone Marrow Transplantation</i> , 2021, 56, 2212-2220.	2.4	5
23	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. <i>Leukemia</i> , 2021, 35, 2885-2894.	7.2	153
24	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 2727-2736.	1.3	0
25	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e801-e809.	0.4	17
26	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	1.3	21
27	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021, 69, 103304.	1.8	12
28	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	4.1	6
29	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	2.4	13
30	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 83-87.	2.0	3
31	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
32	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020, 22, e13206.	1.7	13
33	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
34	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2
35	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
36	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	1.3	1
38	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4
39	Risk factors and outcome of COVID-19 in patients with hematological malignancies. <i>Experimental Hematology and Oncology</i> , 2020, 9, 21.	5.0	119
40	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2261-2269.	2.4	3
41	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	2.4	24
42	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
43	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
44	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2020, 80, 333-341.	3.3	7
45	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
46	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
47	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	2.4	12
48	Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 142-150.	1.3	38
49	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
50	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
51	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). <i>Annals of Oncology</i> , 2019, 30, 612-620.	1.2	88
52	Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1818-1824.	2.0	29
53	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019, 98, 2081-2088.	1.8	16
54	Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 172-177.	2.2	5

#	ARTICLE	IF	CITATIONS
55	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
56	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. <i>Medical Microbiology and Immunology</i> , 2019, 208, 253-258.	4.8	19
57	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
58	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
59	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 740-747.	2.0	5
60	Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. <i>Aids</i> , 2019, 33, 1441-1447.	2.2	13
61	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
62	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
63	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
64	Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019, 62, 418-427.	4.0	3
65	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
66	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. <i>European Journal of Haematology</i> , 2019, 102, 331-340.	2.2	4
67	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
68	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
69	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22
70	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19
71	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018, 35, 79.	2.5	15
72	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018, 67, 805-807.	5.8	12

#	ARTICLE	IF	CITATIONS
73	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.4	15
74	The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2018, 53, 180-187.	2.4	35
75	Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 161-167.	1.8	22
76	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
77	T lymphocytes as therapeutic arsenal for patients with hematological malignancies. <i>Current Opinion in Oncology</i> , 2018, 30, 425-434.	2.4	4
78	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
79	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	2.2	11
80	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
81	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
82	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22
83	Impact of cytomegalovirus <sc>DNA</sc>emia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18
84	A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , 2017, 19, e12729.	1.7	17
85	When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1448-1451.	2.4	4
86	Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2017, 52, 1273-1279.	2.4	11
87	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. <i>Journal of Clinical Virology</i> , 2017, 97, 26-32.	3.1	9
88	Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 134-139.	2.0	24
89	Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 438-444.	2.4	7
90	IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2017, 89, 685-695.	5.0	10

#	ARTICLE	IF	CITATIONS
91	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	5.2	6
92	INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016051.	1.3	18
93	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , 2016, 51, 1307-1312.	2.4	31
94	Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. <i>Bone Marrow Transplantation</i> , 2016, 51, 718-721.	2.4	35
95	Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. <i>Transplant Infectious Disease</i> , 2016, 18, 89-92.	1.7	10
96	Re-examining the relationship between active cytomegalovirus (CMV) infection and acute graft-versus-host disease in allogeneic stem cell transplant recipients in the era of real-time PCR CMV assays. <i>Transplant International</i> , 2016, 29, 126-128.	1.6	6
97	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. <i>Transplant International</i> , 2016, 29, 1196-1204.	1.6	4
98	Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw107.	0.9	36
99	GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. <i>Bone Marrow Transplantation</i> , 2016, 51, 1524-1526.	2.4	6
100	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of postâ€transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	2.2	19
101	Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	16
102	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	3.5	16
103	Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. <i>Annals of Hematology</i> , 2014, 93, 299-307.	1.8	38
104	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
105	Impact of Hyperferritinemia on the Outcome of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 597-601.	2.0	6
106	Updated Experience with Inolimomab as Treatment for Corticosteroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 435-439.	2.0	11
107	Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis. <i>Blood</i> , 2013, 122, 4611-4611.	1.4	0
108	Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2012, 47, 1343-1349.	2.4	13

#	ARTICLE	IF	CITATIONS
109	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 1187-1195.	3.5	15
110	Degree of mucositis and duration of neutropenia are the major risk factors for early posttransplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2012, 88, 46-51.	2.2	20
111	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <i>American Journal of Hematology</i> , 2012, 87, 9-14.	4.1	23
112	Pretransplantation Liver Function Impacts on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Study of 455 Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1653-1661.	2.0	17
113	Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study. <i>International Journal of Hematology</i> , 2011, 93, 458-464.	1.6	55
114	Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 5-10.	2.5	13
115	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <i>Bone Marrow Transplantation</i> , 2011, 46, 690-701.	2.4	18
116	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010, 95, 1176-1182.	3.5	63
117	Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. <i>Bone Marrow Transplantation</i> , 2010, 45, 534-542.	2.4	32
118	MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. <i>Bone Marrow Transplantation</i> , 2010, 45, 1449-1456.	2.4	43
119	Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 413-420.	2.0	67
120	Hepatic Toxicity After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation: Incidence, Characteristics and Risk Factors In a Cohort of 452 Patients.. <i>Blood</i> , 2010, 116, 3495-3495.	1.4	0
121	Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 44, 749-756.	2.4	51
122	Study of Kidney Function Impairment after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 21-29.	2.0	53
123	Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1439-1446.	2.0	79
124	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen. <i>Cytotherapy</i> , 2009, 11, 356-361.	0.7	4
125	Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2009, 21, S35-S37.	2.4	6
126	Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2008, 41, 425-437.	2.4	14



#	ARTICLE	IF	CITATIONS
127	Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 577-584.	1.6	213
128	Results of Compassionate Therapy with Intrathecal Depot Liposomal Cytarabine in Acute Myeloid Leukemia Meningeosis. <i>International Journal of Hematology</i> , 2007, 86, 33-36.	1.6	12
129	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. <i>Blood</i> , 2007, 110, 4925-4925.	1.4	0
130	Encouraging Results with Inolimomab (Anti-IL-2 Receptor) as Treatment for Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1135-1141.	2.0	30